Financial Performance - The company reported a significant revenue decline of 15% year-on-year for 2022, totaling approximately 1.2 billion CNY[21]. - The net profit attributable to shareholders decreased by 20% compared to the previous year, amounting to around 150 million CNY[21]. - The company's operating revenue for 2022 was ¥724,844,899.72, a decrease of 67.99% compared to ¥2,264,174,816.08 in 2021[26]. - The net profit attributable to shareholders was -¥822,822,306.85 in 2022, a decline of 2.43% from -¥803,289,348.21 in 2021[26]. - The cash flow from operating activities was ¥222,189,274.79, down 73.36% from ¥833,892,028.75 in 2021[26]. - The total assets at the end of 2022 were ¥6,562,516,043.19, a decrease of 13.98% from ¥7,628,958,587.57 at the end of 2021[26]. - The company's basic and diluted earnings per share were both -¥1.07 in 2022, a slight decrease of 1.90% from -¥1.05 in 2021[26]. - The weighted average return on equity was -19.80% in 2022, compared to -16.67% in 2021, indicating a worsening financial performance[26]. - The company reported a net loss from non-operating income of -¥13,653,428.14 in 2022, compared to -¥32,839,908.21 in 2021[32]. - Total revenue for 2022 was ¥724,844,899.72, a decrease of 67.99% compared to ¥2,264,174,816.00 in 2021[67]. - Pharmaceutical revenue accounted for ¥708,965,680.76, down 67.50% from ¥2,181,427,500.00 in the previous year[67]. Market Strategy and Outlook - The company plans to invest 100 million CNY in R&D for new product development in the upcoming year[21]. - The company has outlined a market expansion strategy targeting a 25% increase in market share within the next three years[21]. - Future outlook includes a projected revenue growth of 5% for 2023, driven by new product launches and market strategies[21]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[21]. - The company is actively responding to industry challenges and government policies aimed at promoting health and innovation in the pharmaceutical sector[37]. - The company aims to enhance its operational layout and optimize strategies in response to the evolving healthcare landscape[51]. - The company plans to respond to market competition by increasing new product development and expanding sales channels while consolidating traditional core product sales[113]. Research and Development - The company continues to invest in product research and development, including the completion of clinical research for new drugs[40]. - R&D investment accounted for 3.69% of operating revenue, an increase of 2.35 percentage points from 1.34% in the previous year[87]. - The number of R&D personnel increased to 71, representing 7.43% of the total workforce, up from 5.58% in 2021[87]. - Ongoing research projects include the development of traditional Chinese medicine formulations, such as the five-flavor disinfectant drink and the peach-red four-herb soup, to prepare for new drug applications[86]. - The company is conducting pre-IND registration consultations with the US FDA for its Q81/Q90 product, aiming to enhance international recognition[86]. Operational Challenges - The company faced significant challenges in 2022, with a focus on product structure adjustment and refined management to stabilize operations amid a tough economic environment[37]. - The company faced challenges in market expansion due to insufficient working capital affecting marketing investments[72]. - The company is facing significant operational and debt repayment risks in the coming year, indicating major uncertainties regarding its ability to continue as a going concern[171]. - The company has reported a non-operating fund occupation of 457 million yuan by the controlling shareholder, which has not been fully repaid as of the report date[150]. - The company faces risks from policy changes, raw material cost fluctuations, intensified market competition, and challenges in new drug development[111]. Governance and Compliance - The company maintained a governance structure compliant with the Corporate Law and Securities Law, ensuring independent operations from its controlling shareholder[117]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation directly to operational performance[119]. - The company has independent financial management and auditing systems, ensuring no assets are occupied by the controlling shareholder[124]. - The company has implemented a comprehensive information disclosure policy, ensuring timely and accurate communication with investors[119]. - The company is under administrative supervision by the China Securities Regulatory Commission due to violations related to fund occupation and disclosure[190]. Environmental and Social Responsibility - The company emphasizes environmental protection and energy conservation, ensuring compliance with national environmental regulations[110]. - The company has not violated environmental laws in the past three years and has implemented measures to reduce energy consumption and pollution through technological advancements[159]. - The company aims to achieve a harmonious development between business operations and environmental protection[156]. - The company has committed to distributing cash dividends amounting to no less than 30% of the average distributable profit over the next three years[163]. - The company has pledged to allocate at least 10% of the annual distributable profit for cash dividends to minority shareholders[163].

Financial Performance - The company reported a significant financial performance with total revenue reaching 1.5 billion RMB, representing a year-on-year increase of 12%[20]. - The company has provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.65 billion RMB[20]. - The company's operating revenue for 2022 was ¥724,844,899.72, a decrease of 67.99% compared to ¥2,264,174,816.08 in 2021[25]. - The net profit attributable to shareholders for 2022 was -¥822,822,306.85, reflecting a 2.43% increase in losses from -¥803,289,348.21 in 2021[25]. - Total revenue for 2022 was ¥724,844,899.72, a decrease of 67.99% compared to ¥2,264,174,816.00 in 2021[68]. - Pharmaceutical revenue accounted for ¥708,965,680.76, representing 97.81% of total revenue, down 67.50% year-over-year[68]. - The company reported a significant drop in drug wholesale and retail revenue, decreasing by ¥1,239,262,997.29, down 85.44% from the previous year[73]. - The company’s net profit attributable to shareholders was a loss of ¥822,822,306.85, significantly impacted by asset impairment and credit loss provisions[92]. Market Expansion and Product Development - User data indicates a growth in customer base, with active users increasing by 15% to 3 million in 2022[20]. - New product development includes the launch of three innovative herbal medicines, expected to contribute an additional 200 million RMB in revenue[20]. - The company plans to expand its market presence by entering two new provinces in 2023, targeting a 5% market share in these regions[20]. - The company aims to leverage the growing demand for healthcare services, particularly in the context of the aging population and the three-child policy[55]. - The company is actively pursuing innovation in its product development and service delivery to meet evolving consumer health needs[53]. - The company is focused on expanding its market presence and enhancing product development to drive future growth[132]. Research and Development - The company has invested 100 million RMB in R&D for new technologies aimed at improving production efficiency[20]. - The company has invested in R&D, completing projects such as the secondary development of the well-known traditional Chinese medicine Qilin Wan[39]. - R&D investment accounted for 3.69% of operating revenue, an increase of 2.35 percentage points from 1.34% in the previous year[88]. - The number of R&D personnel increased to 71, representing 7.43% of the total workforce, up from 5.58% in 2021[88]. - The company is preparing for the U.S. FDA drug registration of Q81/Q90, with preliminary research and feedback already completed[87]. Financial Management and Governance - The company has no plans to distribute cash dividends or issue bonus shares for the fiscal year[6]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation directly to company performance[120]. - The company strictly adheres to the requirements of the Company Law and Securities Law, ensuring compliance with corporate governance standards[118]. - The board of directors operates transparently and fairly, with a structure that meets legal requirements, ensuring the protection of shareholder rights[119]. - The company has maintained a stable management team, with key executives holding their positions since 2010, ensuring continuity in leadership[128]. Risks and Challenges - The company has identified potential risks in the market, including regulatory changes and competition, which may impact future performance[5]. - The company faces risks from policy changes, market competition, and rising raw material costs, which could impact profitability[112][113]. - The company experienced a resignation of the deputy general manager, Zhuang Qiming, on June 15, 2022, which may impact operational strategies[130]. - The company faces significant operational and debt repayment risks in the coming year, indicating major uncertainties regarding its ability to continue as a going concern[172]. - The company is currently involved in multiple legal disputes regarding unpaid debts and contractual obligations[188]. Compliance and Regulatory Issues - The company has been issued a warning letter by the China Securities Regulatory Commission for failing to disclose information within the statutory period[190]. - The company has acknowledged the need for improved compliance with financial reporting standards to avoid regulatory penalties[190]. - The audit report contains a reserved opinion due to the inability to obtain sufficient audit evidence regarding certain assets and liabilities[175]. - The company faced administrative regulatory measures due to inconsistencies in revenue recognition policies and financial statement consolidation scope[190]. Environmental and Social Responsibility - The company emphasizes environmental protection and energy conservation, aligning with national regulations on clean production and safety management[111]. - The company has taken measures to reduce carbon emissions through process improvements and employee awareness programs[157]. - The company commits to distributing at least 30% of its average distributable profits in cash over the next three years[164]. - The company has not violated environmental laws in the past three years and has implemented measures to reduce energy consumption and pollution through technological advancements[160].

关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广东太安堂药业股份有限公司（以下简称"公司"）于 2023 年 4 月 29 日在 巨潮资讯网（www.cninfo.com.cn）披露了《公司 2022 年年度报告》及其摘要。 为了使广大投资者更全面深入的了解公司情况，公司定于 2023 年 5 月 22 日下午 15:00-17:00 在全景网举办 2022 年度网上业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长、总经理、代行董秘柯少彬先生、财 务总监余祥先生及公司独立董事朱伟。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 19 日（星期五）15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维 码，进入问题征集专题页面。 ...

Financial Performance - The company's revenue for Q1 2023 was ¥139,317,832.02, a decrease of 27.16% compared to ¥191,252,969.09 in the same period last year[5]. - The net loss attributable to shareholders was ¥61,443,810.03, representing a 64.49% increase in losses from ¥37,353,612.37 in the previous year[5]. - Basic earnings per share decreased by 60.00% to -¥0.08 from -¥0.05 in the previous year[5]. - The company's total comprehensive income decreased by 51.20% to ¥21,251,154.20 compared to the previous year[12]. - Net loss for Q1 2023 was ¥62,509,752.43, compared to a net loss of ¥41,251,302.09 in Q1 2022, representing a 51.5% increase in losses[26]. - Other comprehensive income after tax for Q1 2023 was -¥249,560.72, slightly improved from -¥256,856.86 in Q1 2022[27]. Cash Flow - The net cash flow from operating activities was -¥39,735,469.21, a decline of 395.21% compared to a positive cash flow of ¥13,460,157.43 in the same period last year[5]. - Cash inflow from operating activities was ¥190,305,597.74, a decline of 35.7% from ¥296,200,956.85 in the previous year[28]. - Cash inflow from investment activities totaled 73,384,616.90 CNY, compared to 247,300.00 CNY in the same period last year, indicating a substantial increase[30]. - The net cash flow from investment activities was 71,067,089.34 CNY, a recovery from -827,146.81 CNY in the previous year[30]. - Cash inflow from financing activities was 167,719,437.62 CNY, down from 326,200,000.00 CNY year-over-year[30]. - The net cash flow from financing activities was -32,114,102.31 CNY, slightly improved from -33,730,652.58 CNY in the previous year[30]. - Total cash outflow from operating activities was 230,041,066.95 CNY, compared to 282,740,799.42 CNY in the previous year[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,349,408,767.85, down 3.25% from ¥6,562,516,043.19 at the end of the previous year[5]. - Total current assets amounted to CNY 3,486,266,436.81, down from CNY 3,596,883,230.08 at the beginning of the year[22]. - Total non-current assets amounted to CNY 2,863,142,331.04, down from CNY 2,965,632,813.11 at the beginning of the year[22]. - Total liabilities decreased to ¥2,683,267,849.31 from ¥2,835,483,695.60, a reduction of 5.4%[26]. - Total equity attributable to shareholders of the parent company was ¥3,554,542,013.88, down from ¥3,614,367,500.53, a decrease of 1.7%[26]. Operating Activities - Total operating revenue for Q1 2023 was ¥139,317,832.02, a decrease of 27.1% compared to ¥191,252,969.09 in the same period last year[25]. - Total operating costs for Q1 2023 were ¥225,506,907.16, down 6.2% from ¥240,371,640.52 year-on-year[25]. - Cash received from sales of goods and services decreased by 39.86%, amounting to a reduction of ¥101,922,031.69 compared to the previous year[13]. - The company reported a significant increase in sales expenses, totaling ¥25,813,024.60, compared to ¥27,117,040.51 in the previous year[26]. Investments - The company experienced a 29574.33% increase in cash inflow from investment activities, primarily due to the disposal of fixed assets[14]. - Cash paid for fixed assets, intangible assets, and other long-term assets increased by CNY 1,068,680.75, a growth of 1435.50% compared to the previous period, mainly due to the acquisition of fixed assets[15]. - Cash outflow from investment activities increased by CNY 1,243,080.75, a growth of 115.69%, primarily due to the purchase of fixed assets[15]. - Net cash flow from investment activities increased by CNY 71,894,236.15, a growth of 8691.84%, mainly due to the recovery of funds from the disposal of fixed assets[15]. Employee and Tax Expenses - The company paid 35,935,833.25 CNY to employees, a decrease from 40,162,474.03 CNY in the previous year[30]. - The company incurred tax payments of 18,934,534.29 CNY, down from 22,008,591.85 CNY year-over-year[30]. Miscellaneous - The company did not conduct an audit for the first quarter report[31].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a growth of 15% compared to the previous year[20]. - The company's operating revenue for 2022 was ¥724,844,899.72, a decrease of 67.99% compared to ¥2,264,174,816.08 in 2021[25]. - The net profit attributable to shareholders for 2022 was -¥822,822,306.85, representing a slight increase in loss of 2.43% from -¥803,289,348.21 in 2021[25]. - The net cash flow from operating activities decreased by 73.36% to ¥222,189,274.79 in 2022, down from ¥833,892,028.75 in 2021[25]. - The company's total revenue for the reporting period decreased by ¥1,539,329,916.36, representing a decline of 67.99% year-on-year, primarily due to a significant reduction in the pharmaceutical e-commerce retail business[71]. - The revenue from pharmaceutical wholesale and retail dropped by ¥1,239,262,997.29, down 85.44% year-on-year, mainly due to decreased e-commerce sales by a subsidiary[72]. - The company reported a significant drop in quarterly revenue, with Q4 2022 revenue at ¥26,594,861.64, down from ¥191,252,969.09 in Q1 2022[29]. - The company incurred a net loss of -¥677,483,588.78 in Q4 2022, contributing to the overall annual loss[29]. Market Expansion and Strategy - User data indicates that the company has expanded its customer base by 20%, reaching 5 million active users by the end of 2022[20]. - The company has outlined a future outlook projecting a revenue growth of 10% for 2023, driven by new product launches and market expansion strategies[20]. - The company plans to enhance its market presence by entering two new provinces in 2023, aiming for a 5% market share in these regions within the first year[20]. - A strategic acquisition of a smaller pharmaceutical company is in progress, which is anticipated to increase production capacity by 30%[20]. - The company is focusing on expanding its business in the "Internet + healthcare" sector, aligning with national policies to enhance healthcare services[41]. - The company aims to integrate resources across the pharmaceutical industry, hospitals, and internet healthcare to create a unique competitive advantage in the market[52]. Research and Development - Research and development efforts have led to the introduction of three new herbal medicine products, which are expected to contribute an additional 200 million RMB in revenue[20]. - The company invested in R&D, completing projects such as the secondary development of the well-known traditional Chinese medicine Qilin Wan and the IV phase clinical research of a new drug[38]. - The company is conducting pre-IND registration consultations with the US FDA for its Q81/Q90 product, aiming to enhance international recognition[86]. - The company has completed the research on the chemical components of its Qilin Wan product, which will support its clinical applications[86]. - The company is developing a new drug based on the ancient formula "Peach Blossom Four Substance Decoction," preparing for further new drug applications[86]. - The company's R&D investment amounted to ¥26,717,444.44 in 2022, a decrease of 12.11% compared to ¥30,400,042.44 in 2021[87]. - R&D investment accounted for 3.69% of operating revenue in 2022, an increase of 2.35 percentage points from 1.34% in 2021[87]. Operational Efficiency - The company is focusing on improving its supply chain efficiency, targeting a reduction in operational costs by 15% over the next fiscal year[20]. - The company has established 72 fully automated production lines to enhance production capacity and efficiency in traditional Chinese medicine manufacturing[62]. - The company has 18 production lines for traditional Chinese medicine, with 25 exclusive products, including unique varieties such as Qilin Wan and Xin Bao Wan[48]. - The company is addressing the shortage of medicinal materials through a resource survey and species identification project for Bai Rong Cao[86]. Corporate Governance and Compliance - The company has established a performance evaluation and incentive mechanism for directors and senior management, linking their compensation directly to the company's operating performance[119]. - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, institutions, and finance, ensuring autonomous operational capabilities[121]. - The company has established an independent financial management system and internal audit department, ensuring no assets are occupied by the controlling shareholder[124]. - The company has disclosed information accurately and timely, ensuring all shareholders have equal access to information[119]. - The company has implemented a comprehensive internal control system to ensure the authenticity and completeness of financial information[120]. - The company has committed to respecting and protecting the legitimate rights and interests of stakeholders, promoting sustainable and healthy development[120]. Social Responsibility and Environmental Impact - The company actively participated in social responsibility initiatives, enhancing employee rights and corporate culture[40]. - The company emphasizes environmental protection and energy conservation, ensuring compliance with national environmental regulations[110]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[156]. - The company is not classified as a key pollutant discharge unit and has adhered to environmental protection laws and regulations[156]. - The company has undertaken measures to reduce carbon emissions, including process modifications to decrease electricity consumption[156]. Challenges and Risks - The company has indicated uncertainty regarding its ability to continue as a going concern, as reflected in its recent audit report[25]. - The company faces risks from policy changes, raw material cost fluctuations, and intensified market competition, which could impact profitability[111]. - The company is facing significant performance decline and debt repayment risks in the next year, indicating major uncertainties regarding its ability to continue as a going concern[176]. - The audit report indicates a major uncertainty regarding the company's ability to continue as a going concern due to substantial losses and liabilities[171]. Employee and Management Structure - The total number of employees at the end of the reporting period was 955, with 317 in the parent company and 638 in major subsidiaries[142]. - The company has a stable management team, with no significant changes in shareholding among directors and supervisors during the reporting period[128]. - The company has implemented a training program through its management academy to enhance employee skills and operational efficiency[145]. - The company emphasizes a competitive salary and benefits policy to attract and retain talent, aligning with its strategic development[144].

证券代码：002433 证券简称：太安堂 编号：2015003 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|------------------------------|------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | | 广发证券股份有限公司-吴文华（医药行业研究员） | | 时间 | 2015 年 7 月 2 日 | | | 地点 | 公司 | | | 上市公司接待人员 | 董事会秘书陈小卫 | | | 投资者关系活动 | 1 、请问目前公司的经营情况？ | | | 主要内容介绍 | | 公司的经营情况良好，上半年净利润预计同比增长 25%- | | | 35% | ，公司的麒麟丸、心灵丸等独家品种 ...

证券代码：002433 证券简称：太安堂 编号：2015002 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|---------------------------|---------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | | 中信证券股份有限公司-孙渤 | | | 参与单位名称及人员姓名 | | 广东承天传富资产管理有限公司-戴才华 | | | 广东精准投资管理有限公司 | - 庄琪 | | 时间 | 2015 年 5 月 14 | 日 | | 地点 | 公司 | | | 上市公司接待人员 | 董事会秘书陈小卫 | | | 投资者关系活动 | 1 、康爱多在 2015 | 年有那些发展计划 ? | | 主要内容介绍 | | 康爱多将 ...

证券代码：002433 证券简称：太安堂 编号：2015 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|-----------------------------|------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 | | | 参与单位名称及人员姓名 | 国泰基金管理有限公司 | - 方钰涵 | | | | 农银汇理基金管理有限公司-陈继业 | | 时间 | 2015 年 2 月 6 日 | | | 地点 | 公司 | | | 上市公司接待人员 | 董事会秘书陈小卫 | | | 投资者关系活动 | 1 、公司 2014 | 年的基本情况？ | | 主要内容介绍 | | 公司实现销售及利润同比增长，收购广东康爱多连锁药 | | | | 店有限公司 ...

证券代码：002433 证券简称：太安堂 编号：2015004 广东太安堂药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|--------------------------|---------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | | 中国人保资产管理股份有限公司-田垒 | | 时间 | 2015 年 10 月 29 | 日 | | 地点 | 公司 | | | 上市公司接待人员 | 董事会秘书陈小卫 | | | 投资者关系活动 | 1 、目前公司的经营情况？ | | | 主要内容介绍 | | 公司的前三季度经营情况良好，净利润同比增长 25% 左右， | | | | 公司的麒麟丸、心灵丸、丹田降脂丸等独家品种的销售保 ...